Serum MicroRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 2, 2014, Pages 229-237

  Thapa, Dharma R ^a,b   Hussain, Shehnaz K ^b,c   Tran, Wen Ching ^b   D'souza, Gypsyamber ^d   Bream, Jay H ^d   Achenback, Chad J ^e   Ayyavoo, Velpandi ^f   Detels, Roger ^c   Martínez Maza, Otoniel ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HIV; lymphoma; miR 122; miR 21; miR 222; miR 223

Indexed keywords

MICRORNA; MICRORNA 122; MICRORNA 21; MICRORNA 223;

ADULT; AGED; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CONFERENCE PAPER; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EPSTEIN BARR VIRUS INFECTION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SCREENING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MICRORNAS; MIDDLE AGED; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84901484976     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000146     Document Type: Conference Paper

References (76)

1. Cote TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. Int J Cancer. 1997;73:645-650. (Pubitemid 127483058)
2. Beral V, Peterman T, Berkelman R, et al. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991;337:805-809.
3. Raphael M, Borisch B, Jaffe ES. Lymphomas associated with infection by the human immune deficiency virus (HIV). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classi fication of Tumors, Pathology and Genetics of Tumours of Haemotopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001:260-263.
4. Bohlius J, Schmidlin K, Costagliola D, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009; 14:1065-1074.
5. Diamond C, Taylor TH, Aboumrad T, et al. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer. 2006;106:128-135. (Pubitemid 43032557)
6. Long JL, Engels EA, Moore RD, et al. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS. 2008;22:489-496. (Pubitemid 351317290)
7. Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer. 2010;116:5507-5516.
8. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551-2559.
9. d'Arminio Monforte A, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005;165:416-423. (Pubitemid 40280197)
10. Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004;101:317-324. (Pubitemid 38890835)
11. Di Lisio L, Martinez N, Montes-Moreno S, et al. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood. 2012;120: 1782-1790.
12. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
13. Di Lisio L, Sanchez-Beato M, Gomez-Lopez G, et al. MicroRNA signatures in B-cell lymphomas. Blood Cancer J. 2012;2:e57.
14. Jima DD, Zhang J, Jacobs C, et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood. 2010;116:e118-e127.
15. Lenze D, Leoncini L, Hummel M, et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia. 2011;25:1869-1876.
16. O'Hara AJ, Wolfgang V, Dittmer DP. Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood. 2008;111:2347-2353. (Pubitemid 351451443)
17. Navarro A, Gaya A, Martinez A, et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood. 2008;111:2825-2832.
18. Calin GA, Chang-Gong L, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004;101:11755-11760. (Pubitemid 39095368)
19. Robertus JL, Kluiver J, Weggemans C, et al. MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br J Haematol. 2010;149:896-899.
20. Zhang J, Jima DD, Jacobs C, et al. Patterns of micro RNA expression characterize stages of human B-cell differentiation. Blood. 2009;113: 4586-4594.
21. Fischer L, Hummel M, Korfel A, et al. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol. 2011;13:1090-1098.
22. Lawrie CH, Chi J, Taylor S, et al. Expression of micro RNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009;13: 1248-1260.
23. Fassina A, Marino F, Siri M, et al. The miR-17-92 micro RNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest. 2012;92: 1574-1582.
24. Roehle A, Hoefig KP, Repsilber D, et al. Micro RNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008;142:732-744.
25. Lawrie CH, Soneji S, Marafioti T, et al. Micro RNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 2007;121:1156-1161. (Pubitemid 47101656)
26. Culpin RE, Proctor SJ, Angus B, et al. 9 series micro RNA signature differentiates between germinal center and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol. 2010;37:367-376.
27. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation-stage-specific expression of micro RNAs in B-lymphocytes and diffuse B-cell lymphomas. Blood. 2009;113:3754-3764.
28. Li C, Sang-Woo K, Rai D, et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the micro RNA profile of diffuse large B-cell lymphoma. Blood. 2009;113:6681-6690.
29. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumor-associated micro RNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672-675. (Pubitemid 351667616)
30. Fang C, Zhu DX, Dong HJ, et al. Serum micro RNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol. 2012;91: 553-559.
31. Moussay E, Wang K, Cho JH, et al. Micro RNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2011;108:6573-6578.
32. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of micro-RNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117: 3140-3146.
33. Thapa DR, Bhatia K, Bream JH, et al. B-cell activation induced micro RNA-21 is elevated in circulating B cells preceding the diagnosis of AIDS-related non-Hodgkin lymphomas. AIDS. 2012;26:1177-1180.
34. Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. micro RNA-29c and micro RNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009;113:5237-5245.
35. Visone R, Veronese A, Rassenti LZ, et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 2011;118: 3072-3079.
36. Calin GA, Ferracin M, Cimmino A, et al. A micro RNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353:1793-1801. (Pubitemid 41549891)
37. Asslaber D, Pinon JD, Seyfried I, et al. micro RNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood. 2010;115:4191-4197.
38. Rossi S, Shimizu M, Barbarotto E, et al. micro RNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010;116:945-952.
39. Alencar AJ, Malumbres R, Kozloski GA, et al. Micro RNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res. 2011;17:4125-4135.
40. Montes-Moreno S, Martinez N, Sanchez-Espiridion B, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011;118:1034-1040.
41. Breen EC, Hussain SK, Magpantay L, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev. 2011;20:1303-1314.
42. Epeldegui M, Breen EC, Hung YP, et al. Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis. AIDS. 2007;21:2265-2270. (Pubitemid 350287452)
43. Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol. 1993;11:1099-1107. (Pubitemid 23163350)
44. Breen EC, Epeldegui M, Boscardin WJ, et al. Elevated levels of soluble CD44 precede the development of AIDS-associated non-Hodgkin's B-cell lymphoma. AIDS. 2005;19:1711-1712. (Pubitemid 41502693)
45. De Roos AJ, Mirick DK, Edlefsen KL, et al. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res. 2012;72: 4733-4743.
46. Witwer KW, Sarbanes SL, Liu J, et al. A plasma micro RNA signature of acute lentiviral infection: biomarkers of central nervous system disease. AIDS. 2011;25:2057-2067.
47. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318. (Pubitemid 17102758)
48. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34: 374-378. (Pubitemid 36184095)
49. Kosaka N, Iguchi H, Ochiya T. Circulating micro RNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101:2087-2092.
50. Allegra A, Alonci A, Campo S, et al. Circulating micro RNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (Review). Int J Oncol. 2012;41:1897-1912.
51. Houzet L, Yeung ML, de Lame V, et al. Micro RNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology. 2008;5:118.
52. Gupta A, Nagilla P, Le HS, et al. Comparative expression profile of miRNA and mRNA in primary peripheral blood mononuclear cells infected with human immunodeficiency virus (HIV-1). PLoS One. 2011; 6:e22730.
53. Bignami F, Pilotti E, Bertoncelli L, et al. Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. Blood. 2012; 119:6259-6267.
54. Triboulet R, Mari B, Lin YL, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science. 2007;315:1579-1582. (Pubitemid 46449475)
55. Yeung ML, Bennasser Y, Myers TG, et al. Changes in microRNA expression profiles in HIV-1-transfected human cells. Retrovirology. 2005;2:81.
56. Witwer KW, Watson AK, Blankson JN, et al. Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV- 1-infected elite suppressors and viremic patients. Retrovirology. 2012;9:5.
57. Wang X, Ye L, Hou W, et al. Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood. 2009;113:671-674.
58. Huang J, Wang F, Argyris E, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med. 2007; 13:1241-1247. (Pubitemid 47530631)
59. Ahluwalia JK, Khan SZ, Soni K, et al. Human cellular microRNA hsamiR- 29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology. 2008;5:117.
60. Thapa DR, Li X, Jamieson BD, et al. Overexpression of microRNAs from the miR-17-92 paralog clusters in AIDS-related non-Hodgkin's lymphomas. PLoS One. 2011;6:e20781.
61. Wang JF, Yu ML, Yu G, et al. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun. 2010; 394:184-188.
62. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2012;5:492-497.
63. Levine AM, Karim R, Mack W, et al. Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study. Arch Intern Med. 2006;166:405-410.
64. Zon LI, Arkin C, Groopman JE. Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol. 1987;66:251-256. (Pubitemid 17087425)
65. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissuespecific microRNAs from mouse. Curr Biol. 2002;12:735-739.
66. Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol. 2010;8:1002-1012.
67. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43: 27-34. (Pubitemid 44306484)
68. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50:136-142.
69. Xu J, Zhu X, Wu L, et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/beta-catenin pathway. Liver Int. 2012;32:752-760.
70. Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45:355-360.
71. Trebicka J, Anadol E, Elfimova N, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol. 2013;58: 234-239.
72. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106:4402-4407.
73. Fu X, Han Y, Wu Y, et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest. 2011;41:1245-1253.
74. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138:1659-1666.
75. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008; 123:187-194. (Pubitemid 351705208)
76. Ferracin M, Zagatti B, Rizzotto L, et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer. 2010;9:123.